Metsera targets $289m IPO for GLP-1RA development

US-based Metsera is preparing for a significant $289 million IPO as the developer of a weight loss drug, MET-097i, with an elongated half-life, navigates the IPO market in 2025. Metsera is looking to offer more than 17 million shares priced between $15 and $17 for its listing on the Nasdaq. An SEC filing on 27 January outlined the biotech’s intentions to target $250.8 million at the midpoint of the price range, with the potential to reach $289 million if additional shares are purchased by underwriters.

The company plans to utilize the funds from the IPO to propel its glucagon-like peptide-1 receptor agonist (GLP-1RA) asset, MET-097i, into a Phase III trial. Recent results from a Phase IIa trial of MET-097i revealed weight loss of up to 11.3% after three months of treatment, with some patients experiencing up to 20% weight loss. Notably, all 120 patients in the trial achieved clinically significant weight loss, irrespective of the dosage. These positive outcomes have elevated MET-097i’s standing in a competitive landscape of GLP-1RAs that strive to differentiate themselves from established market leaders like Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide by enhancing administration methods or efficacy.

Although MET-097i is administered subcutaneously, similar to other weight loss medications, its distinctive feature lies in its half-life, developed using Metsera’s peptide lipidation platform, HALO. With a half-life of 15 to 16 days, MET-097i surpasses the reported duration of both tirzepatide (Zepbound) and semaglutide (Wegovy) for weight loss.

GlobalData senior analyst Ophelia Chan remarked on the promising results of MET-097i’s Phase II trial, highlighting the drug’s longer half-life compared to its competitors. The positive reception of MET-097i indicates a potential shift in the GLP-1RA market landscape.

Metsera’s substantial $289 million IPO aligns with growing optimism among investors regarding the recovery of the pharma fundraising environment, painting a positive outlook for biotech companies seeking public listings in 2025. This substantial IPO offering from Metsera positions it among the higher-value listings seen since the beginning of 2024. The company’s entry into the IPO market stands as an early indicator of what the year has in store for the biotech sector.